Movement Alert｜EVEREST MED Intraday Rise 5.94% in Regular Trading, mRNA platform hiring and global clinical plans remain in focus

Market Focus10-16

On October 16, EVEREST MED rose 5.94% in Regular Trading, trading at HK$33.6, with turnover of HK$63.45 million.

The move aligns with continued market attention on the company’s recent hiring of two former Moderna cancer-vaccine scientists, an event-driven catalyst tied to its mRNA platform and overseas clinical expansion.

Publicly disclosed details show the two new executives are expected to advance the company’s mRNA platform clinical development in the US and work closely with its China R&D team. The company has said its personalized therapeutic cancer vaccine EVM16 is planned to start an IIT Ib study in the fourth quarter and target a US IND filing in early next year, while EVM14 is expected to complete Phase I work in the first quarter next year. Earlier disclosed interim results showed revenue of RMB1.148 billion, up 157.3% year over year, with attributable loss narrowing to RMB5.94 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment